NewsNovo
Eli Lilly has moved its strategic emphasis from manufacturing capacity to new product launches and acquisitions, a shift that redefines the key metrics for investors evaluating the stock.
The company trades at 38.7 times earnings, a premium to the S&P 500's 21.5 multiple, and management's recent communications indicate that the drivers of this valuation are evolving.
During the fiscal second-quarter 2026 earnings call on August 5, 2026, management highlighted the ongoing U.S.
launch of Foundayo, a new weight-loss pill, and positive results from three late-stage retatrutide trials in obesity. The company also announced agreements to acquire several firms.
Keep reading